Sapreme is dedicated to advancing next-generation macromolecule therapeutics by evading endosomal entrapment, thus improving target interaction. The company's exclusive endosomal evasion platform enhances the effective treatment range by granting access to intracellular targets with minimal adverse effects. This strategy is utilized for Sapreme's internal development pipeline and is open to collaboration, with no restrictions on biologic modality or medical condition.
Sapreme technologies
Headquarters
Netherlands